Clinical & Development Strategy Lead

Apply now

Date: Jun 21, 2019

Location: Anderlecht, Brussels, BE

UCB is a global biopharmaceutical company. We focus on discovering and developing innovative medicines and lateral solutions that can transform the everyday lives of people with severe diseases of the immune system – or the central nervous system.

With more than 7500 people in approximately 40 countries, UCB offers an exciting working environment where initiative can flourish and those with a ‘can-do’ attitude can thrive.  Scientific excellence, innovation, co-creation, lateral thinking, reinventing the way we do things…these are some of the key competencies we are constantly developing, and looking for, at UCB.

At UCB, we put our heart, soul, and skills into making a difference for people living with severe disease. Working together to push the boundaries, we are building the next generation biopharma leader and need exceptional individuals to achieve this goal. We are looking for enthusiastic and talented professionals who thrive on challenge and change, and who want to make a difference and deliver results. Will you join us in our pioneering adventure?

Neurology Clinical and Development Strategy Lead,

Brussels or Braine l’Alleud, Belgium,

other UCB office (UK, US, Germany, France)

 

Help us transform patients’ lives. To strengthen our Neurology Patient Value Unit (nPVU), we are looking to fill the position of Neurology Clinical and Development Strategy Lead.

 

Context

UCB focuses on neurology and immunology. There is a clear and substantial unmet need for many patient populations suffering from severe neurological disorders. UCB has made the conscious strategic decision to invest a significant amount in R&D (above industry average) to deliver new treatment options to patients, and build the basis for sustainable long-term growth to serve the increasing demand for clear differentiation and value for patients. We recognize that radical changes are taking place in the eco-system of care and that we need to evolve accordingly to deliver on our vision. The key element of our evolution is to focus on the delivery of increased patient value.

To formulate and deliver the neurology strategy UCB created The Neurology Patient Value Unit (nPVU) is responsible for the development of the assets post Proof of Concept in Human, their registration launch and commercialization. A diversified and maturing New Meds clinical portfolio of new molecules in clinical development within the core strategy of the neurology PVU require dedicated resources that prepare late stage development activities as well as valuation of assets value for patients, society and UCB.

The recently formed ‘New Patient Value Mission’ has been created to expand the clinical, and commercial capabilities that will focus on designing the strategy for New Meds’ molecules in development as well as the valuation and due diligence of external opportunities. The nNPVM ambition is to ensure UCB growth and sustainability is achieved bringing to neurology patients assets of clear differentiated value. To achieve its goal and ambition the nNPVM will ensure the design of an actionable late stage strategy. This will include accurate quantification of molecule value for patients, UCB and to a broader extend to society. The nNPVM is also responsible for making valuation of future revenues, and all financial estimates that would define return of investment for organic and inorganic assets. The nNPVM will be the key interface between New Meds and nPVU and between BD and nPVU for external opportunities, aligning goals and ensuring focus. This will be achieved by influencing and directing the molecules in development to the most appropriate patient populations, ensuring the most appropriate outcomes and endpoints are used as early as feasible during development. Studies in addition to the key pivotal studies that may be needed to evaluate novel outcomes and endpoints will be considered. nNPVM will be responsible for ensuring a seamless integration into the nPVU portfolio and secure change of accountability from New Medicine post PoC to nPVU. This will include enabling the formation of dedicated new Missions when required. nNPVM will act as an incubator for core development teams while the appropriate new Mission will get formed and take accountability of the new assets. When the future appropriate Mission that would be accountable for the development of the asset is already existing, the nNPVM will facilitate the transition from New Meds and will facilitate and help appropriate resources and capabilities are identified.

To deliver these goals the nNPVM appoints for each of the patient populations of strategic focus and interest Neurology Clinical and Development Strategy Leads and Commercial Leads.

 

Your role

The Neurology Clinical and Development Strategy Lead is responsible to ensure connectivity of the entire value cycle (Patient to Science, Science to Solution, Solution to Patient) both in term of key development activities and clinical studies as well as connecting and guiding the relevant functions and practices. The Neurology Clinical and Development Strategy Lead defines, in collaboration with key functions represented in the PST, nPVU, and practices the global development and commercial strategy for the assigned neurology assets in clinical development. The Neurology Clinical and Development Strategy Lead will be an integral part of the New Meds PSTs that are responsible for development of new assets in neurology, starting from the early clinical development strategy up to and including Clinical Proof of Concept with a focus on Epilepsy and Neurodegenerative diseases.

The Neurology Strategy Development Lead, in collaboration and with the contribution of practices, New Medicines PVU, and other relevant functions, will own the TPVP for the assets in development. The Neurology Clinical and Development Strategy Lead will also ensure that the value to be produced by the asset for patient will be clearly defined and quantified during the asset development to enable value-based reimbursement.

The Neurology Clinical and Development Strategy Lead will work with Business Development and the Scouting team to consider external assets, coordinate and conduct due diligence and ensuring the focus and priority will be given to assets expected to bring clearly definable, competitive and differentiated value for neurology patients.

 

Your responsibilities

Identify patient populations where the asset would create maximum differentiated value

  1. Ensure TPVPs are aligned within nPVU
  2. Ensure single point of contact from the nPVU for New Meds’ assets and representation at PST.
  3. Business valuation and forecasting of neuro assets in development
  4. Ensure assets move from New Meds to nPVU with no gaps and with a seamless integration
  5. Core team and development lead are identified as early as feasible
  6. For assets within the remit of nPVU with no obvious mission as receiver the NPVM will act as incubator and enabler for new mission formation, and the clinical and development lead will ensure continuity holding and ensuring continuity and consistency.

 

Your scope 

In scope

  • Identification for assets in New Meds of value for patients, society and UCB and the way to measure it
  • Orient BD and Scouting activities in patient populations and disease are of relevance for inorganic growth

 Out of scope

  • Evaluation of assets outside of neurology PVU scope

     

Your Key interfaces

New Meds

  • PSTs and PSLs - 
  • nPVU: Insights, Access, HEOR, RWE, Missions & Regions
  • Neuroscience Leadership Team (NSLT), and NMLT: align on Neuro PVS, and new Patient Populations

Practices

  • Clinical and medical, regulatory, safety, marketing

Neurology BD

  • Neuroscience Partnering Committee (NPC) & Corporate Strategy &Development

External

  • Scientific community and KOLs

 

Your competencies        

  • You have a M.D. (or similar degree) with neurology specialty training or equivalent (PhD) in disease area of focus (epilepsy, movement disorders, neurodegenerative diseases). Experience in developing novel treatment for neuro orphan indication is a plus, as it will be highly relevant to have previous experience in developing novel treatments with innovative modalities including biological therapies such as gene therapies and antisense oligonucleotides.
  • You have built experience in developing compounds for CNS indications.
  • You developed a strong experience in clinical and academic research in the TA of neurology, neurodegenerative diseases.
  • You achieved a track record of high impact publications in the field of neurology, in particular in the key area of interest including epilepsy, neurodegeneration and movement disorders.
  • You possess a good knowledge and expertise in the overall Pharma value chain.
  • You are experienced at leading and inspiring teams and influencing junior scientists.

 

Job Location

Global strategic role, depending on the profile and match with specific needs locations in other UCB hubs (Atlanta, RTP, Boston for US) or in Europe Slough, UK, Monheim Germany, or Paris France could be considered.


Job Segment: Clinic, Neurology, Medical, Immunology, Law, Healthcare, Legal

Apply now
Find similar jobs: